Good question: Bevacizumab (Avastin): An anti-angiogenic drug that inhibits vascular endothelial growth factor (VEGF), reducing blood vessel formation in tumors. Pembrolizumab (Keytruda): An immune checkpoint inhibitor targeting PD-1 to enhance the immune system's ability to attack cancer cells. Ipilimumab (Yervoy): Another immune checkpoint inhibitor that targets CTLA-4 to boost immune response against tumors. Atezolizumab (Tecentriq): Targets PD-L1, preventing it from binding to PD-1 and allowing T cells to destroy cancer cells. Cabozantinib (Cabometyx): Inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis. These are just a few!
Could understanding cancer metabolism pave the way for personalized cancer therapies that target a tumor's specific fuel source?
Are there drugs that have been developed to target disrupt cancer metabolism?
Good question:
Bevacizumab (Avastin): An anti-angiogenic drug that inhibits vascular endothelial growth factor (VEGF), reducing blood vessel formation in tumors.
Pembrolizumab (Keytruda): An immune checkpoint inhibitor targeting PD-1 to enhance the immune system's ability to attack cancer cells.
Ipilimumab (Yervoy): Another immune checkpoint inhibitor that targets CTLA-4 to boost immune response against tumors.
Atezolizumab (Tecentriq): Targets PD-L1, preventing it from binding to PD-1 and allowing T cells to destroy cancer cells.
Cabozantinib (Cabometyx): Inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis.
These are just a few!